Kong C, Castro D, Lee J, Piston D
J Mol Endocrinol. 2024; 74(1).
PMID: 39475846
PMC: 11875080.
DOI: 10.1530/JME-24-0060.
Kong C, Castro D, Lee J, Piston D
bioRxiv. 2024; .
PMID: 38798528
PMC: 11118541.
DOI: 10.1101/2024.05.13.593899.
Nakhaee S, Farrokhfall K, Miri-Moghaddam E, Askari M, Amirabadizadeh A, Foadoddini M
BMC Endocr Disord. 2021; 21(1):180.
PMID: 34488743
PMC: 8422785.
DOI: 10.1186/s12902-021-00847-x.
Vuong C, van Uum S, ODell L, Lutfy K, Friedman T
Endocr Rev. 2009; 31(1):98-132.
PMID: 19903933
PMC: 2852206.
DOI: 10.1210/er.2009-0009.
Roche D, Childs E, Epstein A, King A
Psychoneuroendocrinology. 2009; 35(4):596-606.
PMID: 19837518
PMC: 2843791.
DOI: 10.1016/j.psyneuen.2009.09.016.
Stimulation of the hypothalamic-pituitary-adrenal axis with the opioid antagonist nalmefene.
Geer E, Landman R, Wardlaw S, Conwell I, Freda P
Pituitary. 2005; 8(2):115-22.
PMID: 16379031
DOI: 10.1007/s11102-005-5227-6.
Failure of naloxone to antagonize metoclopramide induced prolactin rise.
LAURIAN L, OBERMAN Z, AYALON D, Graf E, Fitermann A, Hoerer E
J Neural Transm. 1981; 52(1-2):49-54.
PMID: 7288437
DOI: 10.1007/BF01253096.
Changes in nalorphine-induced hyperprolactinaemia after bromocriptine or sulpiride administration.
Barreca T, Magnani G, Sannia A, Rolandi E
Eur J Clin Pharmacol. 1982; 22(4):375-6.
PMID: 7106173
DOI: 10.1007/BF00548408.
Influence of low doses of naloxone on pituitary secretion in man.
Rolandi E, Marabini A, Magnani G, Sannia A, Barreca T
Eur J Clin Pharmacol. 1982; 22(3):213-6.
PMID: 6809476
DOI: 10.1007/BF00545217.
Effects of an enkephalin analogue (DAMME) on insulin release from cultured rat islets of Langerhans.
Pierluissi R, Pierluissi J, Ashcroft S
Diabetologia. 1981; 20(6):642-6.
PMID: 6790327
DOI: 10.1007/BF00257434.
Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects.
Roti E, Degli Uberti E, Salvadori S, Bianconi M, Emanuele R, Rotola C
J Endocrinol Invest. 1984; 7(3):211-4.
PMID: 6470436
DOI: 10.1007/BF03348425.
Role of endogenous opiates in the expression of negative feedback actions of androgen and estrogen on pulsatile properties of luteinizing hormone secretion in man.
Veldhuis J, Rogol A, SAMOJLIK E, ERTEL N
J Clin Invest. 1984; 74(1):47-55.
PMID: 6429197
PMC: 425183.
DOI: 10.1172/JCI111417.
Opiates modulate insulin action in vivo in dogs.
Werther G, Joffe S, Artal R, Sperling M
Diabetologia. 1984; 26(1):65-9.
PMID: 6368301
DOI: 10.1007/BF00252266.
Enkephalins and Endorphins. Clinical, pharmacological and therapeutic implications.
Copolov D, Helme R
Drugs. 1983; 26(6):503-19.
PMID: 6360635
DOI: 10.2165/00003495-198326060-00003.
Metabolic studies in chlorpropamide-alcohol flush positive and negative Type 2 (non-insulin dependent) diabetic patients with and without retinopathy.
Barnett A, Spiliopoulos A, Pyke D, Stubbs W, Burrin J, Alberti K
Diabetologia. 1983; 24(3):213-5.
PMID: 6341151
DOI: 10.1007/BF00250165.
Modulation of post-prandial insulin release by ingested opiate-like substances in dogs.
Schusdziarra V, Holland A, Schick R, de la Fuente A, Klier M, Maier V
Diabetologia. 1983; 24(2):113-6.
PMID: 6341135
DOI: 10.1007/BF00297392.
Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers.
Naber D, Pickar D, Davis G, Cohen R, Jimerson D, Elchisak M
Psychopharmacology (Berl). 1981; 74(2):125-8.
PMID: 6267643
DOI: 10.1007/BF00432677.
Endocrine responses to marathon running.
Semple C, Thomson J, Beastall G
Br J Sports Med. 1985; 19(3):148-51.
PMID: 4075064
PMC: 1478253.
DOI: 10.1136/bjsm.19.3.148.
d-Amphetamine raises cortisol levels in schizophrenic patients with and without chronic naltrexone pretreatment.
VAN KAMMEN D, Schulz S
J Neural Transm. 1985; 64(1):35-43.
PMID: 4067601
DOI: 10.1007/BF01259343.
Sexual maturation of the hypothalamus: pathophysiological aspects and clinical implications.
Forest M
Acta Neurochir (Wien). 1985; 75(1-4):23-42.
PMID: 3993451
DOI: 10.1007/BF01406321.
